Drug intelligence / Profile preview

GLIX-23

Development stage: Unknown
Lead developer: Hemispherian
Modality: Small Molecules

Overview

GLIX-23 is a small molecule drug candidate developed by Hemispherian. It is currently in the discovery phase and has not yet entered clinical trials or received regulatory approval. The primary therapeutic area for GLIX-23 is neoplasms (cancers), but specific cancer subtypes or mechanisms of action have not been publicly disclosed as of the latest available information. The drug's mechanism, molecular target, and detailed pharmacological profile remain undisclosed in public sources[1][2]. Hemispherian focuses on developing novel small molecules for oncology indications[4].

Targets

TET2 (Methylcytosine dioxygenase TET2)

Beyond the preview

Go deeper on GLIX-23.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLIX-23.

Explore the full profile